← All trials
NCT05690698
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 9, 2023
- Primary completion
- Jul 15, 2023
- Completion date
- Jul 15, 2023
- First posted
- Jan 19, 2023
- Last posted
- Aug 30, 2023
- Enrollment
- 100
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Alexandria UniversityLead sponsor
- Alexandria UniversityOverall official - principal investigator
- Alexandria UniversityOfficial
- Suez Canal UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.